OBJECTIVES: The aim of this study was to compare high-resolution free induction decay magnetic resonance spectroscopic imaging (FID-MRSI) at 3 T and 7 T in the brain of healthy subjects and to showcase the clinical potential of accelerated FID-MRSI at 7 T in 2 brain tumor cases. MATERIALS AND METHODS: In this institutional review board-approved study, 10 healthy volunteers (8 men/2 women; age: 31 ± 6 years) were measured at 3 T and 7 T (Trio and 7T-Magnetom; Siemens Healthcare, Germany) and 2 patients (a 38-year-old man and a 37-year-old man), 1 with an anaplastic oligoastrocytoma (grade III) and 1 with a low-grade glioma (oligodendroglioma), were measured at 7 T.Free induction decay MR spectroscopic imaging with 3.4 × 3.4 mm in-plane resolution was acquired in 30 minutes/6 minutes (nonaccelerated/accelerated) at both field strengths. In addition, single-slice or multi-slice FID-MRSI at 7 T was measured in the 2 tumor patients at 7 T within 6 minutes/13.3 minutes. Signal-to-noise ratio, Cramer-Rao lower bounds, and parallel imaging efficiency were assessed. High-resolution maps were created for 9 different brain metabolites. RESULTS: At 7 T, 7 of 9 metabolites were reliably mapped over the whole slice but only 3 at 3 T. Parallel imaging efficiency was significantly improved at 7 T. Signal-to-noise ratios were +75%/+66% (P < 0.05) for N-acetylaspartate and +97%/+74%(P < 0.05) for glutamine + glutamate [Glx], and full-widths at half maximum were +112%/+109%(P < 0.05) higher at 7 T than at 3 T (nonaccelerated/accelerated) for N-acetylaspartate. Cramer-Rao lower bounds were more than double at 3 T (P < 0.05). CONCLUSIONS: At 7 T, FID-MRSI allowed the assessment of an extended neurochemical profile and yielded better metabolic maps in only approximately 6 minutes at 7 T than in approximately 30 minutes at 3 T. We found several potentially therapy-relevant neurochemical alterations in brain tumors that highlighted the potential of fast clinical FID-MRSI at 7 T.
OBJECTIVES: The aim of this study was to compare high-resolution free induction decay magnetic resonance spectroscopic imaging (FID-MRSI) at 3 T and 7 T in the brain of healthy subjects and to showcase the clinical potential of accelerated FID-MRSI at 7 T in 2 brain tumor cases. MATERIALS AND METHODS: In this institutional review board-approved study, 10 healthy volunteers (8 men/2 women; age: 31 ± 6 years) were measured at 3 T and 7 T (Trio and 7T-Magnetom; Siemens Healthcare, Germany) and 2 patients (a 38-year-old man and a 37-year-old man), 1 with an anaplastic oligoastrocytoma (grade III) and 1 with a low-grade glioma (oligodendroglioma), were measured at 7 T.Free induction decay MR spectroscopic imaging with 3.4 × 3.4 mm in-plane resolution was acquired in 30 minutes/6 minutes (nonaccelerated/accelerated) at both field strengths. In addition, single-slice or multi-slice FID-MRSI at 7 T was measured in the 2 tumorpatients at 7 T within 6 minutes/13.3 minutes. Signal-to-noise ratio, Cramer-Rao lower bounds, and parallel imaging efficiency were assessed. High-resolution maps were created for 9 different brain metabolites. RESULTS: At 7 T, 7 of 9 metabolites were reliably mapped over the whole slice but only 3 at 3 T. Parallel imaging efficiency was significantly improved at 7 T. Signal-to-noise ratios were +75%/+66% (P < 0.05) for N-acetylaspartate and +97%/+74%(P < 0.05) for glutamine + glutamate [Glx], and full-widths at half maximum were +112%/+109%(P < 0.05) higher at 7 T than at 3 T (nonaccelerated/accelerated) for N-acetylaspartate. Cramer-Rao lower bounds were more than double at 3 T (P < 0.05). CONCLUSIONS: At 7 T, FID-MRSI allowed the assessment of an extended neurochemical profile and yielded better metabolic maps in only approximately 6 minutes at 7 T than in approximately 30 minutes at 3 T. We found several potentially therapy-relevant neurochemical alterations in brain tumors that highlighted the potential of fast clinical FID-MRSI at 7 T.
Authors: Benjamin Spurny; Rene Seiger; Philipp Moser; Thomas Vanicek; Murray B Reed; Eva Heckova; Paul Michenthaler; Alim Basaran; Gregor Gryglewski; Manfred Klöbl; Siegfried Trattnig; Siegfried Kasper; Wolfgang Bogner; Rupert Lanzenberger Journal: Neuroimage Date: 2019-10-10 Impact factor: 6.556
Authors: Gilbert Hangel; Saurabh Jain; Elisabeth Springer; Eva Hečková; Bernhard Strasser; Michal Považan; Stephan Gruber; Georg Widhalm; Barbara Kiesel; Julia Furtner; Matthias Preusser; Thomas Roetzer; Siegfried Trattnig; Diana M Sima; Dirk Smeets; Wolfgang Bogner Journal: Neuroimage Date: 2019-02-14 Impact factor: 6.556
Authors: Eva Heckova; Bernhard Strasser; Gilbert J Hangel; Michal Považan; Assunta Dal-Bianco; Paulus S Rommer; Petr Bednarik; Stephan Gruber; Fritz Leutmezer; Hans Lassmann; Siegfried Trattnig; Wolfgang Bogner Journal: Invest Radiol Date: 2019-04 Impact factor: 6.016
Authors: In-Young Choi; Ovidiu C Andronesi; Peter Barker; Wolfgang Bogner; Richard A E Edden; Lana G Kaiser; Phil Lee; Małgorzata Marjańska; Melissa Terpstra; Robin A de Graaf Journal: NMR Biomed Date: 2020-09-18 Impact factor: 4.044
Authors: Annabelle Shaffer; Susanna S Kwok; Anant Naik; Aaron T Anderson; Fan Lam; Tracey Wszalek; Paul M Arnold; Wael Hassaneen Journal: Front Neurol Date: 2022-04-05 Impact factor: 4.003
Authors: Eva Heckova; Michal Považan; Bernhard Strasser; Stanislav Motyka; Gilbert Hangel; Lukas Hingerl; Philipp Moser; Alexandra Lipka; Stephan Gruber; Siegfried Trattnig; Wolfgang Bogner Journal: Magn Reson Med Date: 2019-08-08 Impact factor: 4.668
Authors: Philipp Moser; Korbinian Eckstein; Lukas Hingerl; Michael Weber; Stanislav Motyka; Bernhard Strasser; Andre van der Kouwe; Simon Robinson; Siegfried Trattnig; Wolfgang Bogner Journal: Magn Reson Med Date: 2019-11-13 Impact factor: 4.668
Authors: B Spurny; T Vanicek; R Seiger; M B Reed; M Klöbl; V Ritter; J Unterholzner; G M Godbersen; L R Silberbauer; D Pacher; S Klug; M E Konadu; G Gryglewski; S Trattnig; W Bogner; R Lanzenberger Journal: Neuroimage Date: 2021-02-28 Impact factor: 7.400
Authors: Andrew A Maudsley; Ovidiu C Andronesi; Peter B Barker; Alberto Bizzi; Wolfgang Bogner; Anke Henning; Sarah J Nelson; Stefan Posse; Dikoma C Shungu; Brian J Soher Journal: NMR Biomed Date: 2020-04-29 Impact factor: 4.044